CA2692814A1 - Purification of factor viii using a mixed-mode or multimodal resin - Google Patents

Purification of factor viii using a mixed-mode or multimodal resin Download PDF

Info

Publication number: CA2692814A1
Authority: CA; Canada
Prior art keywords: factor viii; protein; salt; purification; ethylene glycol
Prior art date: 2007-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2692814

Other languages

English (en)

French (fr)

Inventor

Susanne Bang

Lars Thim

Johan Karlsson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-11

Filing date

2008-07-11

Publication date

2009-01-15

2008-07-11 Application filed by Individual filed Critical Individual

2009-01-15 Publication of CA2692814A1 publication Critical patent/CA2692814A1/en

Status Abandoned legal-status Critical Current

Links

229960000301 factor viii Drugs 0.000 title claims abstract description 75
238000000746 purification Methods 0.000 title claims abstract description 66
239000011347 resin Substances 0.000 title claims abstract description 27
229920005989 resin Polymers 0.000 title claims abstract description 27
102000001690 Factor VIII Human genes 0.000 claims abstract description 105
108010054218 Factor VIII Proteins 0.000 claims abstract description 104
238000000034 method Methods 0.000 claims abstract description 61
238000011068 loading method Methods 0.000 claims abstract description 32
239000000203 mixture Substances 0.000 claims abstract description 24
239000003446 ligand Substances 0.000 claims abstract description 21
230000002209 hydrophobic effect Effects 0.000 claims abstract description 17
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 107
102000004169 proteins and genes Human genes 0.000 claims description 59
108090000623 proteins and genes Proteins 0.000 claims description 59
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 46
235000002639 sodium chloride Nutrition 0.000 claims description 46
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
150000003839 salts Chemical class 0.000 claims description 41
239000012149 elution buffer Substances 0.000 claims description 31
239000000243 solution Substances 0.000 claims description 21
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 16
239000000356 contaminant Substances 0.000 claims description 16
102100026735 Coagulation factor VIII Human genes 0.000 claims description 14
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 11
229910001424 calcium ion Inorganic materials 0.000 claims description 11
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
229920000053 polysorbate 80 Polymers 0.000 claims description 11
239000011534 wash buffer Substances 0.000 claims description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
230000009467 reduction Effects 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 5
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
235000011130 ammonium sulphate Nutrition 0.000 claims description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
235000019270 ammonium chloride Nutrition 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
235000011148 calcium chloride Nutrition 0.000 claims description 2
239000001103 potassium chloride Substances 0.000 claims description 2
235000011164 potassium chloride Nutrition 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 9
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 9
230000008569 process Effects 0.000 abstract description 4
102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 2
108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 2
239000003114 blood coagulation factor Substances 0.000 abstract description 2
230000000694 effects Effects 0.000 description 28
238000010828 elution Methods 0.000 description 20
238000003306 harvesting Methods 0.000 description 15
239000000872 buffer Substances 0.000 description 14
230000003993 interaction Effects 0.000 description 13
239000006167 equilibration buffer Substances 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
239000006172 buffering agent Substances 0.000 description 8
241000700605 Viruses Species 0.000 description 7
238000003556 assay Methods 0.000 description 7
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 7
238000000855 fermentation Methods 0.000 description 7
230000004151 fermentation Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
238000012433 multimodal chromatography Methods 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
238000000926 separation method Methods 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
238000011067 equilibration Methods 0.000 description 6
239000012535 impurity Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000003599 detergent Substances 0.000 description 5
238000001502 gel electrophoresis Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000005498 polishing Methods 0.000 description 5
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 5
238000005406 washing Methods 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229940105778 coagulation factor viii Drugs 0.000 description 4
239000000499 gel Substances 0.000 description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
108010014173 Factor X Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000012539 chromatography resin Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
-1 e.g. Chemical compound 0.000 description 3
230000000415 inactivating effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000000701 coagulant Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
208000031169 hemorrhagic disease Diseases 0.000 description 2
102000057593 human F8 Human genes 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229960003975 potassium Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
102100036537 von Willebrand factor Human genes 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QLAGGJISLHPJHC-UHFFFAOYSA-N 4-sulfanyl-1h-benzimidazole-2-sulfonic acid Chemical compound C1=CC(S)=C2NC(S(=O)(=O)O)=NC2=C1 QLAGGJISLHPJHC-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
108010089996 B-domain-deleted factor VIII Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
239000007987 MES buffer Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
238000005233 VisuLize Factor VIII Antigen Kit Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
229940031675 advate Drugs 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000603 anti-haemophilic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000012930 cell culture fluid Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940083810 helixate Drugs 0.000 description 1
208000002085 hemarthrosis Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229960000900 human factor viii Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002386 leaching Methods 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
239000004137 magnesium phosphate Substances 0.000 description 1
229910000157 magnesium phosphate Inorganic materials 0.000 description 1
229960002261 magnesium phosphate Drugs 0.000 description 1
235000010994 magnesium phosphates Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012092 media component Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)

CA 2692814 2007-07-11 2008-07-11 Purification of factor viii using a mixed-mode or multimodal resin Abandoned CA2692814A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07112287.3		2007-07-11
EP07112287		2007-07-11
PCT/EP2008/059094 WO2009007451A1 (en)	2007-07-11	2008-07-11	Purification of factor viii using a mixed-mode or multimodal resin

Publications (1)

Publication Number	Publication Date
CA2692814A1 true CA2692814A1 (en)	2009-01-15

Family

ID=38472947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2692814 Abandoned CA2692814A1 (en)	2007-07-11	2008-07-11	Purification of factor viii using a mixed-mode or multimodal resin

Country Status (15)

Country	Link
US (1)	US8399620B2 (ru)
EP (1)	EP2167526B1 (ru)
JP (1)	JP5323072B2 (ru)
KR (1)	KR101293504B1 (ru)
CN (1)	CN101730707B (ru)
AT (1)	ATE503763T1 (ru)
AU (1)	AU2008274195B2 (ru)
BR (1)	BRPI0814220B8 (ru)
CA (1)	CA2692814A1 (ru)
DE (1)	DE602008005885D1 (ru)
ES (1)	ES2364118T3 (ru)
NL (1)	NL300663I2 (ru)
PL (1)	PL2167526T3 (ru)
RU (1)	RU2493163C2 (ru)
WO (1)	WO2009007451A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2300497T3 (da) *	2008-06-24	2012-10-29	Octapharma Ag	Fremgangsmåde til oprensning af koagulationsfaktor VIII
AU2009284113B2 (en)	2008-08-21	2015-05-14	Octapharma Ag	Recombinantly produced human factor VIII and IX
US8945895B2 (en)	2009-07-31	2015-02-03	Baxter International Inc.	Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8277649B2 (en)	2009-12-14	2012-10-02	General Electric Company	Membranes and associated methods for purification of antibodies
SI2538968T1 (en) *	2010-02-24	2018-04-30	Chiesi Farmaceutici S.P.A.	A process for the production and purification of recombinant lysosomal alpha-manosidase
TR201807352T4 (tr)	2010-03-30	2018-06-21	Octapharma Ag	Granülosit koloni stimülatör faktörünün saflaştırılmasına yönelik proses, G-CSF.
DK3133157T3 (da)	2010-03-30	2019-08-12	Octapharma Ag	Fremgangsmåde til oprensning af vitamin k-afhængige proteiner
RU2591523C2 (ru) *	2010-11-05	2016-07-20	Ф. Хоффманн-Ля Рош Аг	Оптимизированный метод захвата антител хроматографией смешанного типа
AU2011343813B2 (en)	2010-12-15	2015-05-21	Takeda Pharmaceutical Company Limited	Eluate collection using conductivity gradient
WO2013075740A1 (en)	2011-11-23	2013-05-30	Sanofi	Antibody purification method
CN104884147A (zh)	2012-10-24	2015-09-02	建新公司	使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
US10188965B2 (en)	2012-12-05	2019-01-29	Csl Behring Gmbh	Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en)	2012-12-05	2014-06-05	Csl Limited	Method of purifying therapeutic proteins
CN103396494B (zh) *	2013-04-27	2015-04-01	江苏省疾病预防控制中心	一种凝血因子ix的单克隆抗体
ES2905675T3 (es) *	2013-05-06	2022-04-11	Sanofi Sa	Proceso multietapa continuo para purificar anticuerpos
JP2017519838A (ja) *	2014-06-25	2017-07-20	ジェイエイチエルバイオテックインコーポレイテッド	タンパク質の精製のための方法及び試薬
PL3177317T3 (pl)	2014-08-04	2020-07-27	Csl Limited	Formulacja czynnika viii
KR20170125941A (ko)	2015-03-06	2017-11-15	체에스엘 베링 리컴비넌트 퍼실리티 아게	개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
GB201506117D0 (en)	2015-04-10	2015-05-27	Ge Healthcare Bio Sciences Ab	Method for chromatography
GB201506113D0 (en) *	2015-04-10	2015-05-27	Ge Healthcare Bio Sciences Ab	Method for chromatography
EP3205665A1 (en) *	2016-02-11	2017-08-16	Octapharma AG	Method of separating factor viii from blood products
GB201617240D0 (en) *	2016-10-11	2016-11-23	Profactor Pharma Ltd	Purification process
CN114072420B (zh)	2019-07-04	2024-06-11	康诺贝林伦瑙有限公司	用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2021094344A1 (en)	2019-11-11	2021-05-20	CSL Behring Lengnau AG	Polypeptides for inducing tolerance to factor viii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9302006D0 (sv) *	1992-10-02	1993-06-11	Kabi Pharmacia Ab	Protein formulation
SE9301581D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Protein formulation
SE503424C2 (sv) *	1994-11-14	1996-06-10	Pharmacia Ab	Process för rening av rekombinant koagulationsfaktor VIII
IL157309A0 (en) *	2003-08-07	2004-02-19	Applied Research Systems	Method for the purification of a non-immunoglobulin protein
KR101364001B1 (ko) *	2004-12-23	2014-02-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	관심있는 비타민 ｋ-의존성 단백질을 포함한 조성물 중의단백질 오염물질의 양의 감소
EP1707634A1 (en) *	2005-03-29	2006-10-04	Octapharma AG	Method for isolation of recombinantly produced proteins
DK2300497T3 (da)	2008-06-24	2012-10-29	Octapharma Ag	Fremgangsmåde til oprensning af koagulationsfaktor VIII

2008
- 2008-07-11 KR KR1020107001510A patent/KR101293504B1/ko active IP Right Grant
- 2008-07-11 RU RU2010103528/10A patent/RU2493163C2/ru active
- 2008-07-11 BR BRPI0814220A patent/BRPI0814220B8/pt not_active IP Right Cessation
- 2008-07-11 AU AU2008274195A patent/AU2008274195B2/en not_active Ceased
- 2008-07-11 PL PL08786090T patent/PL2167526T3/pl unknown
- 2008-07-11 AT AT08786090T patent/ATE503763T1/de not_active IP Right Cessation
- 2008-07-11 ES ES08786090T patent/ES2364118T3/es active Active
- 2008-07-11 EP EP08786090A patent/EP2167526B1/en active Active
- 2008-07-11 WO PCT/EP2008/059094 patent/WO2009007451A1/en active Application Filing
- 2008-07-11 CN CN200880023645.XA patent/CN101730707B/zh active Active
- 2008-07-11 US US12/668,530 patent/US8399620B2/en active Active
- 2008-07-11 CA CA 2692814 patent/CA2692814A1/en not_active Abandoned
- 2008-07-11 JP JP2010515524A patent/JP5323072B2/ja active Active
- 2008-07-11 DE DE602008005885T patent/DE602008005885D1/de active Active
2014
- 2014-04-15 NL NL300663C patent/NL300663I2/nl unknown

Also Published As

Publication number	Publication date
AU2008274195A1 (en)	2009-01-15
AU2008274195B2 (en)	2013-09-05
BRPI0814220A2 (pt)	2015-01-06
US20100204452A1 (en)	2010-08-12
EP2167526A1 (en)	2010-03-31
US8399620B2 (en)	2013-03-19
NL300663I2 (ru)	2016-09-22
EP2167526B1 (en)	2011-03-30
BRPI0814220B8 (pt)	2021-05-25
KR101293504B1 (ko)	2013-08-07
RU2010103528A (ru)	2011-08-20
KR20100051620A (ko)	2010-05-17
PL2167526T3 (pl)	2011-09-30
CN101730707B (zh)	2014-12-17
JP5323072B2 (ja)	2013-10-23
ES2364118T9 (es)	2014-05-19
CN101730707A (zh)	2010-06-09
BRPI0814220B1 (pt)	2019-09-17
RU2493163C2 (ru)	2013-09-20
JP2010533150A (ja)	2010-10-21
WO2009007451A1 (en)	2009-01-15
DE602008005885D1 (de)	2011-05-12
ATE503763T1 (de)	2011-04-15
ES2364118T3 (es)	2011-08-25

Legal Events

Date	Code	Title	Description
2014-09-07	FZDE	Discontinued	Effective date: 20140711

Publication	Publication Date	Title
AU2008274195B2 (en)	2013-09-05	Purification of factor VIII using a mixed-mode or multimodal resin
KR101804136B1 (ko)	2017-12-04	응고 인자 ｖｉｉｉ을 정제하는 방법
JP5730211B2 (ja)	2015-06-03	ウイルスのアルギニン不活化
Burnouf‐Radosevich et al.	1992	Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate
US11479578B2 (en)	2022-10-25	Protein purification and virus inactivation with alkyl glycosides
US20130079498A1 (en)	2013-03-28	Process for purifying vitamin k dependent proteins such as coagulation factor ix
JP4250769B2 (ja)	2009-04-08	高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
JP2008511546A (ja)	2008-04-17	タンパク質単離のためのプロセス
JP7144113B2 (ja)	2022-09-29	血液製剤から第ｖｉｉｉ因子を分離する方法
US20210087224A1 (en)	2021-03-25	Compositions and methods for generating modified cryo poor plasma
EA040179B1 (ru)	2022-04-27	Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro
EP3526245A1 (en)	2019-08-21	Purification process of fviii